Request FREE sample PDF
Pharmacy benefit management market
tumor market REPORT OVERVIEW
The global tumor market size is USD 12986.29 million in 2021 and is projected to touch USD 21505.03 million by 2027, exhibiting a CAGR of 8.77% during the forecast period. The global COVID-19 pandemic has been unprecedented and staggering, with the tumour market experiencing higherr-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden spike in CAGR is attributable to demand returning to pre-pandemic levels once the pandemic is over.
Solid tumor are heterotypic collections of many cell types, including cancer cells, cancer stem cells, connective-tissue cells, and immune cells. Solid tumors are classified into two types: benign and malignant. Solid tumor treatment is complex, and it involves coordinated measures by a number of healthcare professionals, including surgeons, radiologists, radiation specialists, oncologists, and others. Surgery is currently the best treatment option for malignant solid tumor. Chemotherapy is typically used in conjunction with other solid tumor treatments such as surgery and radiation. Solid tumor therapies are medications used to treat tumors such as lung cancer, breast cancer, prostate cancer, colorectal cancer, cervical cancer, and others. Solid tumor therapeutics continue to lead the way in oncology treatments as a successful anti-cancer therapy in the global oncology therapeutics market.
As a result, chemotherapy, radiation, and/or surgery are utilized to treat the vast majority of solid tumor. The rising incidence of cancer, rising awareness about cancer and its treatment, and technological breakthroughs in the field of oncology are all contributing to the market's rise.
COVID-19 Impact: COVID-19 Underlying Condition Uplifted the Market Growth
Due to the pandemic, those who already have poor psychological health are at risk for a variety of problems, including an increase in mental illness rates, disruptions to care, prescriptions, and the backbone of support services, as well as a detrimental effect on the market. Furthermore, research indicates that in individuals with a history of mental illness, the outbreak is most likely to exacerbate preexisting symptoms or cause a relapse. Additionally, several nations are spending money on hiring more mental health specialists and on cutting-edge digital and telecommunications solutions. As a result, it will have a favorable effect to the tumor market growth during the forecaster period.
LATEST TRENDS
"Increasing Number of Research and Development Activities to Bolster the Market Growth"
The market's expansion is being driven by an increase in the number of R&D activities. This will create advantageous chances for the expansion of the solid tumours market. Innovative new cancer treatments have been developed that can be used instead of or in addition to chemotherapy, radiation therapy, surgery, or other treatments such as immunotherapy and targeted therapies, which have shown promising results for patients with advanced cancers who have not responded well enough to other treatments. Furthermore, increased investment in advanced technology development, as well as an increase in the number of emerging markets, would create advantageous prospects for solid tumours market expansion during the projection period.
tumor market SEGMENTATION
- By Type
Based on type the market is classified into Prostate-specific antigen (PSA), Prostatic acid phosphatase (PAP), CA 125, Carcinoembryonic antigen (CEA), Alpha-fetoprotein (AFP), Human chorionic gonadotropin (HCG), CA 19-9, CA 15-3, Lactate dehydrogenase (LDH), Neuron-specific enolase (NSE) and others.
- By Application
Based on application the market is classified as commercial or private laboratories, ambulatory care centers and others.
DRIVING FACTORS
"Rising Prevalence of Different Forms of Metastatic Cancers to Advance Up the Market Share"
The increased prevalence of various types of metastatic cancer is expected to boost market growth. The World Health Organization (WHO) estimates that 8.2 million people died as a result of various types of cancer in 2012. The most prevalent cancers were lung, colorectal, breast, and liver cancers, with lung, colorectal, and breast cancers being the most common. The most common solid tumor are brain tumor (medulloblastoma and glioma) and neuroblastoma; rhabdomyosarcoma and osteosarcoma are less common solid cancers.
"The Investments Incurred for Healthcare Infrastructure to Finance the Market Share"
Another key element affecting the growth rate of the solid market is rising healthcare expenditure, which aids in infrastructure improvement. Furthermore, several government organizations intend to improve healthcare infrastructure by boosting financing, which would have an impact on market dynamics.
Furthermore, increased public and private sector attempts to raise awareness, as well as expanding demand for highly effective chemotherapeutic drugs, will drive the solid market forward. Furthermore, the sedentary lifestyle of individuals, as well as the increasing rates of many cases of solid tumors, will result in the growth of the solid tumor market. The rising level of disposable income and surging geriatric population are expected to drive the market's growth rate throughout the forecast period.
RESTRAINING FACTORS
"High Cost Associated with the Treatment to Retard the Market Growth"
The high expense of the treatment, on the other hand, will slow the market's growth rate. The scarcity of skilled specialists and the absence of healthcare facilities in developing economies will put the solid tumor industry under strain. Furthermore, rigorous regulatory rules and a lack of public awareness may constrain and impede market throughout the projection period.
tumor market REGIONAL INSIGHTS
"North American to Rule the Market owing to Advanced Healthcare Infrastructure"
Because of the increased occurrence of solid tumors and technical advancements in treatment, North America dominates the solid tumor market share. Because of the region's great advancement in precision medicine. Furthermore, sophisticated cancer testing in this country is linked to its genome sequencing research expertise and huge patient base in urban regions. The growing senior population and rising levels of disposable income in this region. Furthermore, rising healthcare expenditures and the presence of significant key competitors will boost the market's growth rate even higher.
KEY INDUSTRY PLAYERS
"Prominent Manufacturers to Contribute Towards Expansion of Market"
The report is an extensive research which presents the historic and futuristic performance of industry with competitive landscape analysis which incorporates prominent key players, and revenue trends of industry. The report provides substantial analysis of company profiling, growth insights, supply-demand chain, and production and consumption demand, business expansion strategies adopted by top key players. The information is a collusion of latest technological developments, trends, production lines mergers and acquisitions, market study and other factors.
List of Market Players Profiled
- Beckman, Dickinson and Company (BD) Diagnostics (U.S.)
- Abbott Diagnostics Ltd. (U.S.)
- Aspira (Correlogic Systems, Inc.) (U.S.)
- NeoGenomics (Clarient,Inc.) (U.S.)
- Epigenomics AG (Germany)
- Siemen (Germany)
- Thermo Fisher Scientific (U.S.)
- Agilent Technologies, Inc. (U.S.)
- Roche Diagnostics (Switzerland)
REPORT COVERAGE
The report anticipates a detailed analysis of the global market size at the regional and national level, the segmentation market growth and market share. The prime objective of the report is to help user understand the market in terms of definition, market potential, influencing trends, and the challenges faced by the market. Analysis of sales, the impact of the market players, recent developments, opportunity analysis, strategic market growth analysis, territorial market expansion, and technological innovations are the subject matter explained in the report.
REPORT COVERAGE | DETAILS |
---|---|
Market Size Value In |
US$ 12986.29 Million in 2021 |
Market Size Value By |
US$ 21505.03 Million by 2027 |
Growth Rate |
CAGR of 8.77% from 2021 to 2027 |
Forecast Period |
2022-2027 |
Base Year |
2023 |
Historical Data Available |
Yes |
Regional Scope |
Global |
Segments Covered |
Type and Application |
Frequently Asked Questions
-
What value is the tumor market expected to touch by 2027?
The global tumor market is expected to reach USD 21505.03 million by 2027.
-
What CAGR is the tumor market expected to exhibit by 2027?
The tumor market is expected to exhibit a CAGR of 8.77% by 2027.
-
Which are the driving factors of the tumor market?
Rising prevalence of different forms of metastatic cancers and the investments incurred for healthcare infrastructure are the driving factors of the tumor market.
-
Which are the top companies operating in the tumor market?
Hoffmann-La Roche, Johnson & Johnson, Novartis, AstraZeneca, Biogen Idec, Boehringer Ingelheim, GlaxoSmithKline, Eli Lilly, Kyowa Hakko Kirin, Abbott Laboratories, Baxter International and others are the top companies operating in the tumor market.